SLNO Quote, Financials, Valuation and Earnings

Axsome Therapeutics has a net margin of -- compared to Soleno Therapeutics's net margin of -63.08%. Soleno Therapeutics's return on equity of -- beat Axsome Therapeutics's return on equity of -244.32%.

Soleno Therapeutics has a consensus price target of $108.63, signalling upside risk potential of 48.27%. On the other hand Axsome Therapeutics has an analysts' consensus of $177.35 which suggests that it could grow by 66.89%. Given that Axsome Therapeutics has higher upside potential than Soleno Therapeutics, analysts believe Axsome Therapeutics is more attractive than Soleno Therapeutics.

Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.883, suggesting its less volatile than the S&P 500 by 11.73%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than Axsome Therapeutics quarterly revenues of $118.8M. Soleno Therapeutics's net income of -$56M is higher than Axsome Therapeutics's net income of -$74.9M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,760.36x versus 13.20x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

BridgeBio Pharma has a net margin of -- compared to Soleno Therapeutics's net margin of -4506.12%. Soleno Therapeutics's return on equity of -- beat BridgeBio Pharma's return on equity of --.

Soleno Therapeutics has a consensus price target of $108.63, signalling upside risk potential of 48.27%. On the other hand BridgeBio Pharma has an analysts' consensus of $54.18 which suggests that it could grow by 50.95%. Given that BridgeBio Pharma has higher upside potential than Soleno Therapeutics, analysts believe BridgeBio Pharma is more attractive than Soleno Therapeutics.

Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.078, suggesting its more volatile than the S&P 500 by 7.822%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than BridgeBio Pharma quarterly revenues of $5.9M. Soleno Therapeutics's net income of -$56M is higher than BridgeBio Pharma's net income of -$265.1M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,760.36x versus 30.09x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Legend Biotech has a net margin of -- compared to Soleno Therapeutics's net margin of 14.09%. Soleno Therapeutics's return on equity of -- beat Legend Biotech's return on equity of -15.44%.

Soleno Therapeutics has a consensus price target of $108.63, signalling upside risk potential of 48.27%. On the other hand Legend Biotech has an analysts' consensus of $77.99 which suggests that it could grow by 127.51%. Given that Legend Biotech has higher upside potential than Soleno Therapeutics, analysts believe Legend Biotech is more attractive than Soleno Therapeutics.

Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison Legend Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Legend Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Legend Biotech pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than Legend Biotech quarterly revenues of $186.5M. Soleno Therapeutics's net income of -$56M is lower than Legend Biotech's net income of $26.3M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Legend Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,760.36x versus 9.99x for Legend Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of -- compared to Soleno Therapeutics's net margin of -57.51%. Soleno Therapeutics's return on equity of -- beat Madrigal Pharmaceuticals's return on equity of -63.91%.

Soleno Therapeutics has a consensus price target of $108.63, signalling upside risk potential of 48.27%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $414.07 which suggests that it could grow by 26.71%. Given that Soleno Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Soleno Therapeutics is more attractive than Madrigal Pharmaceuticals.

Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.683, suggesting its less volatile than the S&P 500 by 168.299%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $103.3M. Soleno Therapeutics's net income of -$56M is higher than Madrigal Pharmaceuticals's net income of -$59.4M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,760.36x versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.